This past April, Mount Sinai oncologist Joshua Brody and his team announced a clinical trial that delivers immune modulators directly to the tumor environment that stimulate a patient’s immune system ...
More information: Joshua D. Brody et al, Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial, Blood Journal (2025). DOI: 10.1182/blood ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback